Nektar Therapeutics (NKTR), which announced this morning that efficacy data previously generated by Eli Lilly (LLY) for rezpegaldesleukin that were presented at the September 2022 EADV Congress were incorrectly calculated by Lilly, has filed a complaint in San Francisco federal court that accuses Lilly of breach of contract, negligent misrepresentation, unfair competition and other wrongdoing, reported Reuters. Nektar seeks compensatory and punitive damages, among other remedies, the report noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NKTR: